Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 08:38 am IST
Share
Kwang Dong Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 695.22 million compared to KRW 487.66 million a year ago. Net income was KRW 3,000.08 million compared to KRW 2,338.04 million a year ago. Basic earnings per share from continuing operations was KRW 73 compared to KRW 57 a year ago. Diluted earnings per share from continuing operations was KRW 73 compared to KRW 57 a year ago. Basic earnings per share was KRW 73 compared to KRW 57 a year ago.
For the six months, sales was KRW 1,263.9 million compared to KRW 993.49 million a year ago. Net income was KRW 10,587.03 million compared to KRW 8,491.03 million a year ago. Basic earnings per share from continuing operations was KRW 258 compared to KRW 207 a year ago. Diluted earnings per share from continuing operations was KRW 258 compared to KRW 207 a year ago. Basic earnings per share was KRW 258 compared to KRW 207 a year ago.
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.
KWANG DONG PHARMACEUTICAL CO., LTD. 